Global Leukemia Therapeutics Market Growth of 8.44% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Vendors: Novartis, AbbVie, Amgen - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Leukemia Therapeutics Market 2016-2020" report to their offering.

The analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

One of the key trends for market growth will be the rise in the development of combination therapies. Combination therapies for the treatment of leukemia were available only in the form of combination chemotherapy drugs.

The some of the approved combinations are chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. Also, it has been observed that vendors are showing more interest in the development of combination therapies to treat various leukemias.

Questions Answered:

  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals
  • Altor BioScience
  • Amgen
  • ARIAD Pharmaceuticals
  • Arno Therapeutics
  • Astex Pharmaceuticals
  • AstraZeneca
  • Baxter Healthcare
  • Bayer HealthCare
  • Bellicum Pharmaceuticals
  • Bioge

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Pipeline portfolio

PART 06: Market landscape

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market

PART 09: Global ALL therapeutics market

PART 10: Global AML therapeutics market

PART 11: Global CML therapeutics market

PART 12: Geographical segmentation

PART 13: Market drivers

PART 14: Impact of drivers

PART 15: Market challenges

PART 16: Impact of drivers and challenges

PART 17: Market trends

PART 18: Vendor landscape

PART 19: Key vendor analysis

PART 20: Appendix

PART 21: About the Author

For more information about this report visit http://www.researchandmarkets.com/research/vf4mbm/global_leukemia

For more information on this topic, please visit the Oncology Drugs section of the Research and Markets Blog.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs